|486.09||+12.67||+2.68%||Vol 51.06K||1Y Perf -23.49%|
|Feb 2nd, 2023 12:30 DELAYED|
|1.58 0.33%||- -|
|Target Price||621.67||Analyst Rating||Strong Buy 1.33|
|Potential %||28.71||Finscreener Ranking||★★★★ 52.96|
|Insiders Trans % 3/6/12 mo.||-/-/-100||Value Ranking||★★★+ 52.23|
|Insiders Value % 3/6/12 mo.||-/-/-100||Growth Ranking||★★ 44.32|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-100||Income Ranking||— -|
|Price Range Ratio 52W %||43.39||Earnings Rating||Buy|
|Market Cap||14.50B||Earnings Date||16th Feb 2023|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||16th Feb 2023|
|Estimated EPS Next Report||3.45|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||156.81K|
|Avg. Monthly Volume||148.24K|
|Avg. Quarterly Volume||186.14K|
Bio-Rad Laboratories Inc. Class A (NYSE: BIO) stock closed at 473.42 per share at the end of the most recent trading day (a 1.27% change compared to the prior day closing price) with a volume of 163.05K shares and market capitalization of 14.50B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 8000 people. Bio-Rad Laboratories Inc. Class A CEO is Norman Schwartz.
The one-year performance of Bio-Rad Laboratories Inc. Class A stock is -23.49%, while year-to-date (YTD) performance is 12.59%. BIO stock has a five-year performance of 86.14%. Its 52-week range is between 344.63 and 670.615, which gives BIO stock a 52-week price range ratio of 43.39%
Bio-Rad Laboratories Inc. Class A currently has a PE ratio of -2.10, a price-to-book (PB) ratio of 1.48, a price-to-sale (PS) ratio of 5.09, a price to cashflow ratio of 47.80, a PEG ratio of 2.32, a ROA of -41.67%, a ROC of -47.65% and a ROE of -56.29%. The company’s profit margin is -69.91%, its EBITDA margin is -273.90%, and its revenue ttm is $2.07 Billion , which makes it $83.72 revenue per share.
Of the last four earnings reports from Bio-Rad Laboratories Inc. Class A, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $3.45 for the next earnings report. Bio-Rad Laboratories Inc. Class A’s next earnings report date is 16th Feb 2023.
The consensus rating of Wall Street analysts for Bio-Rad Laboratories Inc. Class A is Strong Buy (1.33), with a target price of $621.67, which is +28.71% compared to the current price. The earnings rating for Bio-Rad Laboratories Inc. Class A stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Bio-Rad Laboratories Inc. Class A has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Bio-Rad Laboratories Inc. Class A has a Buy technical analysis rating based on Technical Indicators (ADX : 8.87, ATR14 : 15.05, CCI20 : 101.56, Chaikin Money Flow : 0.18, MACD : 13.22, Money Flow Index : 52.69, ROC : 4.00, RSI : 63.04, STOCH (14,3) : 72.66, STOCH RSI : 0.38, UO : 59.37, Williams %R : -27.34), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Bio-Rad Laboratories Inc. Class A in the last 12-months were: Ajit Ramalingam (Option Excercise at a value of $0), Ajit Ramalingam (Sold 897 shares of value $438 216 ), Allison Schwartz (Option Excercise at a value of $0), Andrew J. Last (Option Excercise at a value of $0), Dara Wright (Option Excercise at a value of $0), Diane Dahowski (Option Excercise at a value of $0), Ilan Daskal (Option Excercise at a value of $0), Michael Crowley (Option Excercise at a value of $0), Norman Schwartz (Option Excercise at a value of $4 212 310), Simon May (Option Excercise at a value of $0), Timothy S. Ernst (Option Excercise at a value of $0)
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.